I

Iambic Therapeutics

AI-driven discovery for oncology and neurology

Director/Senior Director - Immunology

Full-Time
No salary listed
Expert
PhD
San Diego, CA, USA
In Person
Biology & Biotech

About the job

Requirements
  • A PhD in immunology or a related field, with substantial immunology training and typically 15 or more years of relevant experience, including significant industry experience in small-molecule discovery.
  • A track record leading cross-functional small-molecule programs from hit identification through development candidate nomination, with ownership of biology strategy, stage gates, and milestones.
  • Deep expertise in innate and/or adaptive immunology and extensive experience with primary-cell and ex vivo studies, including multiparameter flow cytometry and relevant functional readouts.
  • Experience designing and interpreting in vivo efficacy, pharmacodynamic, and mechanistic studies, including model selection, pharmacokinetics/pharmacodynamics, species translation, and biomarker strategy.
  • Experience developing and transferring robust assay cascades to contract research organizations or automation/high-throughput screening platforms, using orthogonal assays and counterscreens to confirm on-target activity and control for donor variability and assay artifacts.
  • Strong people leadership and executive communication skills, including mentoring, performance management, team development, and data-driven recommendations.
Responsibilities
  • Define and execute biology strategies for small-molecule discovery programs, translating disease and immune biology into in vitro, ex vivo, and in vivo evidence packages that guide medicinal chemistry from hit identification through development candidate nomination and investigational new drug-enabling studies.
  • Lead immunology strategy from target validation and hit identification through lead optimization, development candidate nomination, and investigational new drug-enabling studies, integrating disease biology with structure-activity relationships, DMPK/PK/PD, safety, target engagement, and translational biomarkers.
  • Oversee disease-relevant studies using primary human immune cells, whole blood or peripheral blood mononuclear cells, and tissues to assess mechanism, potency, selectivity, target engagement, and immune function while accounting for donor variability and biological context.
  • Define and oversee efficacy, mechanistic, and pharmacokinetic/pharmacodynamic studies, including model and species selection, endpoints, exposure-response relationships, tissue pharmacology, and translation to human biomarkers; critically interpret results.
  • Drive cross-functional decision-making with Chemistry, DMPK, Safety, Translational, and Computational teams, and partner with artificial intelligence and machine learning scientists to apply computational approaches that accelerate hypothesis generation, data interpretation, and program decisions.
  • Lead project teams, set scientific direction, and manage and develop scientists and associates.
  • Oversee contract research organizations and other partners, ensuring clear goals, timelines, budgets, deliverables, data quality, and appropriate standard operating procedure- and good laboratory practice-aligned practices.
Desired Qualifications
  • Experience using patient-derived samples, translational biomarkers, and high-dimensional data to bridge preclinical and clinical studies.
  • Familiarity with artificial intelligence and machine learning-enabled drug discovery and collaboration with computational biology, data science, or cheminformatics teams.
  • Experience with investigational new drug-enabling studies.

About the company

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Iambic filed an IPO on September 21, 2026, after $207.9 million cash.
  • Revenues reached $18 million over the twelve months ended June 30, 2026.
  • ClinicalTrials.gov shows IAM1363 recruiting 383 patients across 53 sites, including EU expansion.

What critics are saying

  • IAM1363 remains unproven; Phase 1 completion sits in 2028, delaying any approval.
  • Iambic's revenue still depends on partnerships; AbbVie and IPO proceeds fund the burn.
  • If AbbVie walks and IAM1363 fails, Iambic becomes a platform story without assets.

What makes Iambic Therapeutics unique

  • Enchant v3 spans 6,000+ molecular properties across 16 modalities, compressing discovery cycles.
  • AbbVie's September 21, 2026 collaboration validates Iambic's platform with another pharma heavyweight.
  • IAM1363 reached Phase 1 from AI design, proving platform-to-clinic execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Company Match
  • Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-3%
Antlers American
Oct 14th, 2026
Iambic prices $150M IPO at $16 per share, files IND for brain-penetrant cancer drug IAM217

Iambic Therapeutics, an AI-driven drug developer, priced its initial public offering at $16.00 per share, selling 9,375,000 shares for expected gross proceeds of $150.0 million. The underwriters have a 30-day option to buy up to 1,406,250 more shares. Shares are expected to begin trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker "IAM." The offering is due to close on October 16, 2026. J.P. Morgan, Jefferies, BofA Securities, and Citigroup are joint book-running managers. Iambic also submitted an Investigational New Drug application to the US Food and Drug Administration for IAM217, a potentially brain-penetrant KIF18A inhibitor. The Phase 1/2 trial would target triple-negative breast cancer, ovarian cancer, and other solid tumours. In a preclinical model, IAM217 produced about 90% regression of established intracranial tumours.

Intelligence360
Oct 5th, 2026
Iambic Therapeutics raises $66.5M to advance AI-driven drug discovery platform

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission to raise $66.5 million in new funding. The filing was made under Regulation D or Section 4(a)(5) of the Securities Act of 1933, which allows companies to sell securities without registration. Iambic Therapeutics is a drug discovery company that uses AI and automated chemistry and biology experimentation to accelerate pharmaceutical development. The company's platform integrates proprietary AI technologies, including Enchant and NeuralPLexer, for multimodal endpoint prediction. The company previously advanced a novel drug candidate to clinical trials in approximately two years and maintains a diverse preclinical pipeline. Iambic is led by Chief Executive Officer Tom Miller.

PR Newswire
Sep 21st, 2026
AbbVie partners with Iambic to accelerate AI-driven drug discovery in immunology, neuroscience and oncology

AbbVie and Iambic Therapeutics have entered into a multi-year collaboration to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology. The partnership will combine Iambic's molecular superintelligence platform with AbbVie's therapeutic expertise to develop small molecule therapies with first-in-class and best-in-class potential. The collaboration will utilise Enchant v3, Iambic's next-generation multimodal transformer model trained on over 6,000 molecular properties. This technology is designed to optimise candidate properties simultaneously, reducing drug discovery timelines whilst improving success rates. Under the agreement, Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated through the collaboration. The partnership aims to accelerate the discovery process and deliver breakthrough medicines to patients more quickly.

Associated Press
Sep 21st, 2026
Iambic unveils Enchant v3 AI model with 41B parameters to accelerate drug discovery

Iambic, a clinical-stage life science and technology company, has launched Enchant v3, the latest version of its AI-driven multimodal transformer model for drug discovery and development. The model features 41 billion parameters and has been pretrained on 4.5 trillion tokens. Enchant v3 can predict more than 6,000 molecular properties across 16 biomedical modalities, including text, assay data, molecule structure, protein structure, images, multi-omics, biologics, clinical trial data, and pharmacokinetics. The system is designed to integrate diverse data sources and improve prediction accuracy as the model scales. Iambic initially launched Enchant in 2024. The company says its platform combines AI with automated chemistry and biology experimentation, and it previously discovered a novel drug candidate that advanced to clinical trials in approximately two years.

Intelligence360 News
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.